Apogee Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APGE research report →
Range $89 – $140
Price Chart
About the company
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD.
- CEO
- Michael Thomas Henderson
- IPO
- 2023
- Employees
- 261
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on APGE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.36B
- P/E
- -31.12
- PEG
- 6.57
- P/S
- 0.00
- P/B
- 8.53
- EV/EBITDA
- -28.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -29.88%
- ROIC
- -25.23%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,418,000+0.0%
- Op Income
- $-285,595,000
- Net Income
- $-255,843,000-40.5%
- EPS
- $-4.22-27.9%
- OCF Growth
- -32.9%
- FCF Growth
- -35.0%
- 52W High
- $135.09
- 52W Low
- $35.39
- 50D MA
- $134.18
- 200D MA
- $92.32
- Beta
- 0.34
- RSI (14)
- 79
- Avg Volume
- 2.82M
No earnings-call transcripts are available for APGE yet.
- Free Float
- 92.4%
- Shares Outstanding
- 61.88M
- Float Shares
- 57.17M
of shares held by institutions
240 13F filers
Buy/sell ratio 0.08. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vr Adviser, LLC | 8.49M | 0 |
| Blackrock, Inc. | 5.51M | ▲ 1.42M |
| Vanguard Group Inc | 2.86M | ▲ 612.19K |
| Hbk Investments L P | 2.85M | ▲ 2.85M |
| Vanguard Capital Management LLC | 2.57M | ▲ 70.02K |
| Fmr LLC | 2.49M | ▼ 6.77M |
| Janus Henderson Group Ltd. | 2.36M | ▲ 297.99K |
| State Street Corp | 2.30M | ▲ 134.78K |
| Driehaus Capital Management LLC | 1.74M | ▼ 180.70K |
| Goldman Sachs Group Inc | 1.69M | ▲ 1.04M |
| Balyasny Asset Management L.P. | 1.67M | ▲ 1.23M |
| Glazer Capital, LLC | 1.64M | ▲ 1.64M |
Held by 86 ETFs
Biggest fund positions in APGE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 3, 26 | Fairmount Funds Management LLC | sell | 51,166 |
| Sep 3, 26 | Fairmount Funds Management LLC | sell | 6,743,321 |
| Sep 3, 26 | Fairmount Funds Management LLC | sell | 47,758 |
| Sep 3, 26 | Fairmount Funds Management LLC | sell | 10,370 |
| Sep 3, 26 | Fairmount Funds Management LLC | sell | 14,461 |
| Sep 3, 26 | Fairmount Funds Management LLC | sell | 7,657 |
| Sep 3, 26 | McKenna Mark C. | sell | 20,000 |
| Sep 3, 26 | McKenna Mark C. | sell | 150,000 |
| Sep 3, 26 | McKenna Mark C. | sell | 10,370 |
| Sep 3, 26 | McKenna Mark C. | sell | 14,461 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APGE coverage
Recent articles, reports, and earnings notes.
No research on APGE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APGE report →AbbVie Completes Acquisition of Apogee Therapeutics
prnewswire.com · Sep 3
Deutsche Bank AG Acquires New Stake in Apogee Therapeutics Inc. $APGE
defenseworld.net · Aug 23
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
benzinga.com · Aug 12
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
globenewswire.com · Aug 10
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells $737,935.00 in Stock
defenseworld.net · Aug 10
California State Teachers Retirement System Raises Position in Apogee Therapeutics Inc. $APGE
defenseworld.net · Aug 10
Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders?
gurufocus.com · Jul 31
Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders?
prnewswire.com · Jul 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.